Medicinal Products For The Blood And Blood-Forming Organs Recombinant Clotting Factor Vii A Concentrate. 1. The Subject Of The Order Is The Supply Of A Concentrate Of Recombinant Coagulation Factor Viia - Hereinafter Referred To As Coagulation Factor, In Order To Secure The Continuity Of Treatment Of Patients With Hemophilia Type A And B, Complicated With An Inhibitor And Acquired Hemophilia A. 2. Total Quantity (Purchase Quantity): 11,000 Mg 3. Dosage Proportions - In Accordance With Swz 4. The Clotting Factor Concentrate Must Be Delivered With A Kit Enabling Its Administration. 5. When Selecting The Most Advantageous Offer, The Ordering Party Reserves The Right To Reduce The Purchase Of The Medicinal Product, But Not By More Than 20% Of Each Part Of The Above-Mentioned. The Subject Of The Order, If The Amount Allocated For The Execution Of The Order Is Exceeded Or If Objective And Justified Needs Arise, In Particular Changes In Patient Demand. 6. Pursuant To Art. 257 Of The Public Procurement Law. The Contracting Authority May Invalidate The Contract Award Procedure If The Public Funds That The Contracting Authority Intended To Use To Finance All Or Part Of The Contract Were Not Awarded To It. 7. Distribution List Of Direct Recipients For Whom The Purchase In Question Is Made Together With The Ordered Above-Mentioned. The Number Of The Subject Of The Order Needed To Purchase, In Order To Ensure Uninterrupted Implementation Of The Health Policy Program Of The Minister Of Health Entitled The National Program For The Treatment Of Patients With Hemophilia And Related Hemorrhagic Disorders For 2024-2028 Will Be Provided To The Selected Contractor By The National Blood Center After Signing The Contract, In Accordance With The Reported Current Demand.
We takes all possible care for accurate & authentic tender information, however Users are requested to refer Original source of Tender Notice / Tender Document published by Tender Issuing Agency before taking any call regarding this tender.
